[1] Ferlay, J., Soerjomataram, I., Dikshit, R., et al. (2015) Cancerincidence and Mortality Worldwide: Sources, Methods and Major Patterns in Globocan 2012. International Journal of Cancer, 136, E359-E386.
https://doi.org/10.1002/ijc.29210
[2] National Comprehensive Cancer Network. (2018) NCCN Clinical Practice Guidelines in Oneology. Hepatobiliary Cancers. Fort Washington PA: National Comprehensive Cancer Network.
[3] Forner, A., Reig, M. and Bruix, J. (2018) Hepatocellular Carcinoma. The Lancet, 391, 1301-1314.
https://doi.org/10.1016/S0140-6736(18)30010-2
[4] Lin, C.L. and Kao, J.H. (2013) Risk Stratification for Hepatitis B Virus Related Hepatocellular Carcinoma. Journal of Gastroenterology and Hepatology, 28, 10-17.
https://doi.org/10.1111/jgh.12010
[5] Dai, S., Jia, R., Zhang, X., et al. (2014) ThePD-1 /PD-Ls Pathway and Autoimmune Diseases. Cellular Immunology, 290, 72-79.
https://doi.org/10.1016/j.cellimm.2014.05.006
[6] Gettinger, S., Rizvi, N.A., Chow, L.Q., et al. (2016) Nivolumabmonotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 34, 2980-2987.
https://doi.org/10.1200/JCO.2016.66.9929
[7] Weber, J.S., D’Angelo, S.P., Minor, D., et al. (2015) Nivolumab versus Chemotherapy in Patients with Advanced Melanoma Who Progressed after Anti-CTLA-4 Treatment (Checkmate 037): A Randomised, Controlled, Open-Label, Phase 3 Trial. The Lancet Oncology, 16, 375-384.
[8] Garon, E.B., Rizvi, N.A., Hui, R., et al. (2015) Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 372, 2018-2028.
https://doi.org/10.1056/NEJMoa1501824
[9] Chakravarti, N. and Prieto, V.G. (2015) Predictive Factors of Activity of Anti-Programmed Death-1/Programmed Death Ligand-Drug: Immunohistochemistry Analysis. Translational Lung Cancer Research, 4, 743.
[10] Feng, D., Hui, X., Lu, S.-C., et al. (2017) Initial Experience of Anti-PD1 Therapy with Nivolumab in Advanced Hepatocellular Carcinoma. Oncotarget, 8, 96649-96655.
https://doi.org/10.18632/oncotarget.20029
[11] El-Khoueiry, A.B., Sangro, B., Yau, T., et al. (2017) Nivolumab in Patients with Advanced Hepatocellular Carcinoma (Checkmate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. The Lancet, 389, 2492-2502.
[12] Truong, P., Rahal, A. and Kallail, K.J. (2016) Metastatic Hepatocellular Carcinoma Responsive to Pembrolizumab. Cureus, 8, e631.
https://doi.org/10.7759/cureus.631
[13] Zhu, A.X., Finn, R.S., Edeline, J., et al. (2018) Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib (Keynote-224): A Non-Randomised, Open-Label Phase 2 Trial. The Lancet Oncology, 19, 940-952.
[14] Wainberg, Z.A., Segal, N.H., Jaeger, D., et al. (2017) Safety and Clinical Activity of Durvalumab Monotherapy in Patients with Hepatocellular Carcinoma (HCC). Journal of Clinical Oncology, 35, 4071.
https://doi.org/10.1200/JCO.2017.35.15_suppl.4071
[15] Sangro, B., Gomez-Martin, C., De, I.M.M., et al. (2013) A Clinical Trial of CTLA-4 Blockade with Tremelimumab in Patients with Hepatocellular Carcinoma and Chronic Hepatitis C. Journal of Hepatology, 59, 81-88.
https://doi.org/10.1016/j.jhep.2013.02.022
[16] Duffy, A.G., Ulahannan, S.V., Makorova-Rusher, O., et al. (2017) Tremelimumab in Combination with Ablation in Patients with Advanced Hepatocellular Carcinoma. Journal of Hepatology, 66, 545-551.
https://doi.org/10.1016/j.jhep.2016.10.029
[17] Patel, S.A. and Minn, A.J. (2018) Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. Immunity, 48, 417-433.
https://doi.org/10.1016/j.immuni.2018.03.007
[18] Austin, G.D., Drew, P., David, E.K., et al. (2017) Tremelimumab: A Monoclonal Antibody against CTLA-4—In Combination with Radiofrequency Ablation (RFA) in Patients with Biliary Tract Carcinoma (BTC). Journal of Clinical Oncology, 35, 316.
[19] Taylor, M., Dutcus, C.E., Schmidt, E, et al. (2016) A Phase 1b Trail of Lenvatinib (LEN) plus Pembrolizumab (PEM) in Patients with Selected Solid Tumors. Annals of Oncology, 27, 266-295.
[20] Kato, T., Bao, X., Macgrath, S., et al. (2016) Lenvatinibmesilate (LEN) Enhanced Antitumor Activity of a PD-1 Blockade Agent by Potentiating Th1 Immune Response. Annals of Oncology, 27, 2PD.